Verona Pharma Share Discussion Threads

[boystown] 29/12/2021 14:26

I've also held a few of these since the days of reasonable hope (c.8 years I think???) I'd more or less given up on them having managed to lose close to 60% on the effers, and was just looking. With a mkt cap of now $422m, surely it's all over as regards any potential excitement? I'd be very glad to hear that I'm wrong though; any thoughts from anyone who half knows what they're talking about :-) ??

[digger18] 28/12/2021 09:57

I have also been in since 2009 and suffered the massive dilution. However, The recent cardiac results were good and no doubt required by the FDA. I also remember there were cases in an earlier trial, with an
Increase in heart rate, so it’s good that is not deemed to be problem. I am also very happy that the P3 end point targets are based on FEV and general improvement in well being. FEV has always been good in every previous trial, so I personally believe that the prospects for success are good, and on that basis, I look forward to 2022.

[haff1] 24/12/2021 11:38

...Back to where they nearly were before! But lets hope the surge continues....

[tradertrev] 24/12/2021 09:39

Blimey, these have actually gone up! Hearing the shares have attracted some broker support Stateside, but not seen the articles myself.

[tradertrev] 01/12/2021 11:00

I probably started my holding 6-7 years ago, so I share a fair bit of your pain!

[haff1] 01/12/2021 09:55

I've been in VRP for over 10 years and it's yet to stand up to its original potential. It's been increditably slow and has seen constant devaluation of the share price from the start....

[tradertrev] 30/11/2021 12:08

what is it that you expected to have happened by now that hasn't?
They've set out a clear timetable by which things should happen and are broadly sticking to it.
I'd agree the waiting seems endless, but in reality it isn't.

[haff1] 30/11/2021 10:45

...the dissappointment here seems endless......

[haff1] 29/9/2021 10:42

....beginning to think there isn't even jam tomorrow..........

[tradertrev] 05/8/2021 21:21

While the Q2 report suggests the possibility of some slippage in the Phase 3 timelines due to study recruitment challenges amid the continuing pandemic (not really a surprise) there does however appear to be some improvement in the liquidity runway:

Q2 comment - The Company believes our cash and cash equivalents at June 30, 2021, together with the recently received $25.0 million Nuance payment, the recent and anticipated future receipts from the U.K. tax credit program and funding expected to become available under the $30.0 million debt financing facility secured in November 2020 will enable us to fund our planned operating expenses and capital expenditure requirements THROUGH AT LEAST 2023. (my capitals)

Q1 comment - We believe that our cash and cash equivalents as of March 31, 2021, and together with funding expected to become available under both the Term Loan and from cash receipts from U.K. tax credits will enable us to fund our planned operating expenses and capital expenditure requirements INTO 2023. (my capitals)

During Q2 the company issued and sold the equivalent of 54,338 ADSs at average price of $7.23 raising c.$0.4m under their ($100m) At The Market issuance/sale facility. This is effectively a tap facility and explains why any share price surges are always short-lived. Management seem determined to keep a lid on the share price!!

[haff1] 03/8/2021 11:44

...will this ever fly?

[tradertrev] 07/7/2021 09:34

Bid offer spread a meagre 51% on last night's close!!!

[haff1] 02/7/2021 09:13

...but investers see it as too far off to be interested as yet......

[haff1] 10/6/2021 13:35

now this is what we've been waiting for for years.....this is very good news for VRP..

[haroldthegreat] 10/6/2021 11:00

Vote of confidence in the product

[tradertrev] 10/6/2021 10:58

from a friend...

Nuance founder Mark Lotter built AstraZeneca's business in China, which has been highly successful in the respiratory market.
Nuance has a nebuliser platform of its own.
Nuance owns the rights in China to Parexel's Exparel, a significant product already in the US. Parexel would not have licensed this product to any old outfit.

Could be better news than it first appeared. Last trade in pre-market at $7.70 according to Seeking Alpha

[timbo003] 10/6/2021 07:14

A bit of good news released this morning (for a change).....

[tradertrev] 20/5/2021 07:51

Almost 700k ADRs traded over the past two days. Hopefully we are clearing an overhang, although perhaps not fully done yet.

[haff1] 19/5/2021 08:40

Need the share price to follow......

[tradertrev] 18/5/2021 22:08

V strong after hours in US! Volume looks good too.

[haff1] 04/5/2021 14:48

...and now even below that level..........

[haff1] 04/5/2021 08:21

?...I've seen this all before here....we are back to where we were in early January... so the "progress" in the last 3 months is gone: lost...

[tradertrev] 02/5/2021 22:27

Is that the dire lack of long term progress in the last 3 months you are referring to?